does tirzepatide cause heart problems Semaglutide may reduce events more than Mechanisms of action, benefits, and

Patient Profile Patients who were overweight or obese Had cardiovascular disease (CVD) Did not have diabetes Finding of the Study Wegovy was found to have contributed to a reduced risk of heart attack, stroke, death or other related medical conditions by 57% when compared with Mounjaro Major heart events occurred in 15 people using Wegovy, whereas it major events occurred in 39 people who took Mounjaro (an alternate weight loss medicine) Wegovy showed about a 29% lower CVD risk compared with tirzepatide Weight loss treatments generally lead to patients feeling fuller for longer, despite a reduced calorie diet Unpacking the Findings: Why Wegovy May Contribute to Heart Health Wegovy works by mimicking GLP-1, a naturally occurring hormone that: Reduces inflammation in blood vessels Improves overall blood flow Helps stabilise fatty deposits (plaques) in the arteries Lowers the chance of clot formation in the blood Taking Wegovy can provide beneficial cardiovascular effects and can protect against heart attacks and strokes - even before major weight loss is required or occurs

NMN is a direct precursor that the body converts into NAD+

The body is producing compensatory responses

Current evidence suggests these medications lead predominantly to fat loss, but some lean mass loss may occur during weight reduction, particularly if patients are eating too little overall or not consuming enough protein